TrialOrphanet journal of rare diseases2021

Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.

Karina Forde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.